More than an accessory: implications of type III transforming growth factor-β receptor loss in prostate cancer

被引：15

作者：

Ajiboye, Seun ^{[2
]}

Sissung, Tristan M.

Sharifi, Nima ^{[3
]}

Figg, William D. ^{[1
,2
]}

机构：

[1] NCI, Clin Pharmacol Program, Med Oncol Clin Res Unit, Med Oncol Branch,Ctr Canc Res, Bethesda, MD 20892 USA

[2] NCI, Mol Pharmacol Sect, Bethesda, MD 20892 USA

[3] Univ Texas SW Med Ctr Dallas, Dept Internal Med, Div Hematol & Oncol, Dallas, TX USA

来源：

BJU INTERNATIONAL | 2010年 / 105卷 / 07期

基金：

美国国家卫生研究院;

关键词：

betaglycan; TGF beta III receptor; prostate cancer; testosterone; TUMOR-SUPPRESSOR; CELL-MIGRATION; BETAGLYCAN; ACTIVINS; INHIBINS; ACTIVATION; EXPRESSION;

D O I：

10.1111/j.1464-410X.2009.08999.x

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

The type III transforming growth factor-beta receptor (TGF beta R3, betaglycan), a tumour suppressor, is the most frequently lost TGF beta pathway component. This event appears to be very important in the transition of the TGF beta pathway from having tumour-suppressor activity in early prostate tumour development, to having tumour-promoting activity in metastatic disease. Moreover, loss of the TGF beta R3 can also affect the cellular response towards testosterone, inhibin/activin, and dysregulate growth-factor pathways that mediate growth and angiogenesis. In this review we discuss how TGF beta R3 normally functions as an accessory protein in the TGF beta pathway, how its loss is related to tumour progression, and the treatment implications of TGF beta R3 loss in individuals with prostate cancer.

引用

页码：913 / 916

页数：4

共 21 条

[1]

ANDRES JL, 1992, J BIOL CHEM, V267, P5927

[2] Systemic administration of a soluble betaglycan suppresses tumor growth, angiogenesis, and matrix metalloproteinase-9 expression in a human xenograft model of prostate cancer [J].

Bandyopadhyay, A ;

Wang, L ;

Lóepz-Casillas, F ;

Mendoza, V ;

Yeh, IT ;

Sun, LZ .

PROSTATE, 2005, 63 (01) :81-90

[3] Functional roles for the cytoplasmic domain of the type III transforming growth factor β receptor in regulating transforming growth factor β signaling [J].

Blobe, GC ;

Schiemann, WP ;

Pepin, MC ;

Beauchemin, M ;

Moustakas, A ;

Lodish, HF ;

O'Connor-McCourt, MD .

JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (27) :24627-24637

[4] The role of inhibins and activins in prostate cancer pathogenesis [J].

Dowling, CR ;

Risbridger, GP .

[5] Role of transforming growth factor beta in human cancer [J].

Elliott, RL ;

Blobe, GC .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (09) :2078-2093

[6] Regulation of gonadotropins by inhibin and activin [J].

Gregory, SJ ;

Kaiser, UB .

SEMINARS IN REPRODUCTIVE MEDICINE, 2004, 22 (03) :253-267

[7] Cancer statistics, 2008 [J].

Jemal, Ahmedin ;

Siegel, Rebecca ;

Ward, Elizabeth ;

Hao, Yongping ;

Xu, Jiaquan ;

Murray, Taylor ;

Thun, Michael J. .

CA-A CANCER JOURNAL FOR CLINICIANS, 2008, 58 (02) :71-96

[8]

Kang HY, 2009, J BONE MINER RES, V24, P1180, DOI [10.1359/JBMR.090219, 10.1359/jbmr.090219]

[9]

KOLESAR JM, 2008, PHARMACOTHERAPY PATH, P2207

[10] BETAGLYCAN PRESENTS LIGAND TO THE TGF-BETA SIGNALING RECEPTOR [J].

LOPEZCASILLAS, F ;

WRANA, JL ;

MASSAGUE, J .

CELL, 1993, 73 (07) :1435-1444

← 1 2 3 →